• Home
  • Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.

Author List
Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D
Publication
Journal for immunotherapy of cancer
Publication ID (Profile URL)
https://researcherprofiles.org/profile/1215022
Publication Year
2017
PubMed ID
28923100
Publication Title
Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 09 19; 5(1):75.
Publication Medline TA
J Immunother Cancer
Date
2017-09-19